However, blocking tumor-derived cytokines (“tumorkines”), such as activin receptor (ACVR2) ligands (e.g., activins, myostatin and GDF11 [4,10,11]), by ACVR2 antagonism has attenuated muscle atrophy and improved survival in experimental cancer [8,12]. The gene discussed is MSTN; the disease is cancer.